Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Dr Reddys Laboratories (RDY) over the last 7 years, with Q3 2025 value amounting to -$6.3 million.

  • Dr Reddys Laboratories' Gains from Investment Securities rose 6121.67% to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year decrease of 38587.23%. This contributed to the annual value of -$42.0 million for FY2025, which is 1052.63% down from last year.
  • Per Dr Reddys Laboratories' latest filing, its Gains from Investment Securities stood at -$6.3 million for Q3 2025, which was up 6121.67% from -$8.5 million recorded in Q2 2025.
  • Dr Reddys Laboratories' Gains from Investment Securities' 5-year high stood at -$6.3 million during Q3 2025, with a 5-year trough of -$16.2 million in Q3 2024.